Open AccessIn vitro activity and beta-lactamase stability of cefodizime, an aminothiazolyl iminomethoxy cephalosporin
Author(s) -
Brian E. Scully,
K Jules,
Harold C. Neu
Publication year - 1983
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.23.6.907
Subject(s) - microbiology and biotechnology , moxalactam , cefoxitin , cefotaxime , ceftazidime , proteus vulgaris , citrobacter freundii , cephalosporin , bacteroides fragilis , providencia , enterobacter cloacae , biology , klebsiella pneumoniae , citrobacter , enterobacter , staphylococcus aureus , antibiotics , escherichia coli , bacteria , biochemistry , genetics , gene , pseudomonas aeruginosa
Cefodizime, an iminomethoxy aminothiazolyl cephalosporin similar to moxalactam and ceftazidime, was less active (minimal inhibitory concentration, 1.6 to 12 micrograms) than cefazolin or cefotaxime against Staphylococcus aureus and Staphylococcus epidermidis. It inhibited Haemophilus and Neisseria spp. at less than 0.5 microgram/ml. It did not inhibit methicillin-resistant staphylococci, enterococci, or Listeria spp. and was 8- to 32-fold less active than cefotaxime, moxalactam, or ceftazidime against Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Providencia spp., and Serratia spp. Cefotaxime-resistant Enterobacter cloacae, Citrobacter freundii, and Proteus vulgaris were resistant to cefodizime. Cefodizime was less active than cefoxitin or moxalactam against Bacteroides fragilis. Cefodizime was not hydrolyzed by common plasmid or chromosomal beta-lactamases, and it inhibited type I beta-lactamases.